Evolving DLBCL Treatment Landscape: Interpreting ASH 5-Year Polatuzumab Data in Clinical Practice : Episode 1
Advances in DLBCL Management: Long-Term Treatment Outcomes
Experts discuss the 5-year efficacy and safety outcomes of polatuzumab in diffuse large B-cell lymphoma (DLBCL), highlighting its meaningful progression-free survival (PFS) and overall survival (OS) results for first-line patients with DLBCL and emphasizing key long-term safety considerations for clinicians.
Video content above is prompted by the following:
- Please provide an overview of the 5-year efficacy and safety outcomes from the recent ASH data on polatuzumab in DLBCL.
- What do these data mean for patients with first-line DLBCL and why are the PFS and OS results clinically meaningful?
- What are the most significant long-term safety considerations that clinicians should know?
Recent Videos
Related Content
